Harvard Apparatus Regenerative Technology Inc. logo

Harvard Apparatus Regenerative Technology Inc. (HRGN)

Market Open
10 Aug, 20:00
OTC PINK OTC PINK
$
1. 00
0
0%
$
17.58M Market Cap
- P/E Ratio
- Div Yield
106 Volume
- Eps
$ 1
Previous Close
Add Transaction
Day Range
1 1
Year Range
0.96 2.22
Want to track HRGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

HRGN trading today higher at $1, an increase of 0% from yesterday's close, completing a monthly decrease of -20% or -$0.25. Over the past 12 months, HRGN stock lost -45.6522%.
HRGN is not paying dividends to its shareholders.
The last earnings report, released on May 18, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0333%, based on the last three reports.
Harvard Apparatus Regenerative Technology Inc. has completed 1 stock splits, with the recent split occurring on Dec 22, 2017.
The company's stock is traded on one exchange.

HRGN Chart

People also search for

Decker Manufacturing Corporation
$ 57.01
0%
Cannabix Technologies Inc.
$ 0.39
+2.0574%
VicapSys Life Sciences Inc.
$ 1.45
0%
Nuo Therapeutics Inc.
$ 0.85
0%
Quantumzyme Corp.
$ 0.8
+33.3333%

Harvard Apparatus Regenerative Technology Inc. (HRGN) FAQ

What is the stock price today?

The current price is $1.00.

On which exchange is it traded?

Harvard Apparatus Regenerative Technology Inc. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is HRGN.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 17.58M.

Has Harvard Apparatus Regenerative Technology Inc. ever had a stock split?

Harvard Apparatus Regenerative Technology Inc. had 1 splits and the recent split was on Dec 22, 2017.

Harvard Apparatus Regenerative Technology Inc. Profile

Biotechnology Industry
Healthcare Sector
Junli He CEO
OTC PINK Exchange
09074M202 CUSIP
US Country
8 Employees
- Last Dividend
22 Dec 2017 Last Split
- IPO Date

Overview

Harvard Apparatus Regenerative Technology Inc., also known as HART, is a pioneering clinical-stage biotechnology company that has taken a focused approach towards developing regenerative medicine treatments specifically tailored for disorders of the gastrointestinal system, along with conditions affecting other organs due to cancer, trauma, or congenital defects. The company, which initiated its operations in 2009 and is based in Holliston, Massachusetts, rebranded from Biostage, Inc. to its current name in July 2023. The strategic vision of HART is centered on leveraging organ-regeneration technology to offer innovative solutions for the repair or replacement of diseased or damaged organs, thereby addressing a significant unmet medical need in the field of regenerative medicine.

Products and Services

  • Cellspan Esophageal Implant

    The flagship product candidate of HART, the Cellspan Esophageal Implant, is at the forefront of addressing severe esophageal diseases. This groundbreaking technology is designed to cater to patients suffering from critical ailments affecting the esophagus, including but not limited to traumatic injuries, severe caustic burns, tissue damage resulting from aggressive chemoradiation therapy, congenital birth defects, and conditions necessitating the reconstruction of the esophageal tract. By harnessing the power of regenerative medicine, the Cellspan Implant offers a promising treatment alternative aimed at restoring normal function and improving the quality of life for patients afflicted with these complex esophageal conditions.

  • Organ-Rejuvenation Technology

    HART's pipeline is enriched with advanced organ-rejuvenation technologies dedicated to the repair or replacement of diseased or damage organs. The scope of these technologies encompasses a wide range of conditions, with the potential to revolutionize treatment approaches for multiple organs beyond the esophagus, including the colon and uterus. The aim is to provide therapeutic options for wound repair and reconstruction, thereby contributing to the field of regenerative medicine with solutions that promote healing, recovery, and the restoration of organ functionality in cases of trauma, cancer, or birth defects.

  • Longevity Products

    Aside from its clinical-stage endeavors, HART also proffers a line of Longevity products that underline its commitment to personal healthcare and wellness. This product range features longevity dietary supplements that are meticulously developed to support and enhance the overall health and well-being of individuals. Positioned at the intersection between advanced biotechnology and preventive healthcare, these supplements embody HART’s dedication to fostering longer, healthier lives through scientific innovation. By integrating cutting-edge research in regenerative medicine with practical applications in daily health maintenance, HART's Longevity products aim to empower individuals to take proactive steps towards sustaining their health and vitality.

Contact Information

Address: 84 October Hill Road
Phone: 774 233 7300